Shares in shipper PRGN rallied over 500% in the last seven trading days.
However, the company recently sold all of its assets to pay down debt and has very little cash left.
Even PRGN’s… Read more
EBIO’s main drug failed two Phase 3 studies in a row.
However, last month its share price rose 300% on speculation the drug might work after all.
Yesterday EBIO squashed these rumors confirming the… Read more